RIO DE JANEIRO, April 29, 2024 /PRNewswire/ -- TIM S.A ("TIM") announces that its Annual Report on Form 20-F (the "20-F"), reporting its financial and operational data for financial year ended December 31, 2023, was filed with the U.S. Securities and Exchange Commission, or the SEC, and with the Brazilian Securities and Exchange Commission, the Comissão de ValoresMobiliários, or CVM, on April 29, 2024. The document has been posted on TIM's website, https://ri.tim.com.br/.
The 20-F contains detailed information about TIM, including certifications under the U.S. Sarbanes-Oxley Act, which attest to the effectiveness of TIM's internal controls and procedures. TIM independent auditors, Ernst & Young AuditoresIndependentesS.SLtda., issued an audit opinion on the financial statements and the effectiveness of internal controls over financial reporting as of December 31, 2023.
TIM's shareholders may receive a hard copy of this document, which contains the Company's complete audited financial statements, free of charge, upon request. Requests should be directed to:
Investor Relations Department JoãoCabral de MeloNeto Avenue, 850 ? South Tower ? 12th Floor Brazil: 22775-057 Rio de Janeiro, RJ ? Brasil Phone: +55 (21) 98113-6363 E-mail: [email protected]
Olo Inc. , a leading restaurant technology provider, today announced an expanded partnership with TRAY, an innovative Point of Sale and restaurant management platform geared toward Enterprise restaurants, to offer Olo Pay card-present payment...
Whitefort Capital Management, LP (together with its affiliates, "Whitefort Capital," "us" or "we"), which is a long-term investor and the second largest shareholder of Arbutus Biopharma Corp. ("Arbutus" or the "Company") with an ownership interest...
Today Domo announced IT solutions provider Zirous has joined its Partner Program. As a certified full reseller, referral, and implementation partner, Zirous will empower its customers with the Domo platform, making data visible and actionable across...
Verint® will conduct a conference call on Tuesday, June 4, 2024 at 4:30 p.m. ET to review its first quarter financial results (for the quarter ended April 30, 2024) and discuss its outlook. An earnings press release will be issued after the market...
ImmunityBio, Inc. today announced the publication of three podcasts with UroToday highlighting the company's recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive...
Halespring, a pioneering mental health technology startup, is excited to announce the opening of its crowdfunding campaign on WeFunder, the leading SEC regulated equity crowdfunding site. Halespring is dedicated to transforming the mental healthcare...
